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Apoptosis, referred to as programmed cell 
death, is one of the most important events in 
the cell fate. Several cells undergo apoptosis 
every day in physiological and pathological 
settings in the body. When a cell undergoes 
apoptosis, phosphatidylserine (PS) is exposed 
on the outer leaflet of the plasma membrane 
and signals phagocytes to engulf the apoptotic 
cells (Ravichandran and Lorenz, 2007). Several 
receptors for PS are expressed on phagocytes 
and are involved in clearing apoptotic cells 
(Ravichandran and Lorenz, 2007; Zhou, 2007; 
Nagata et al., 2010). For example, T cell im-
munoglobulin– and mucin domain–containing 
molecule 4 (TIM-4), TIM-1, and TIM-3 are 
expressed on macrophages and/or dendritic cells 
and mediate engulfment of apoptotic cells 
upon binding PS (Kobayashi et al., 2007; Miyani-
shi et al., 2007). BAI1 (brain-specific angiogenesis 
inhibitor 1; Park et al., 2007) and stabilin-2 
(Park et al., 2008), which are expressed on 
neuron (Mori et al., 2002) and the sinusoidal 
endothelial cells of the spleen, lymph nodes, 
and BM (Harris et al., 2007), respectively, were 
also reported to be PS receptors for apoptotic 
cells. Engulfment of apoptotic cells also involves 
the bridging molecules that recognize PS. Milk 
fat globule EGF factor 8 (MFG-E8), which is 
expressed by tingible body macrophages and 
follicular dendritic cells at the germinal centers 
in the spleen and lymph nodes—intermediates 
between apoptotic cells and phagocytes—by 
binding both PS and v3 or v5 integrin on 
the phagocytes, stimulating the engulfment of 
apoptotic cells (Hanayama et al., 2002). Similarly, 
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When a cell undergoes apoptosis, phosphatidylserine (PS) is exposed on the outer leaflet of 
the plasma membrane. PS acts as an “eat-me” signal to direct phagocytes expressing PS 
receptors to engulf the apoptotic cell. We recently reported that the immunoreceptor 
CD300a, which is expressed on myeloid cells, is a PS receptor. We show that CD300a does 
not facilitate macrophage phagocytosis of apoptotic cells. Instead, CD300a delivers an 
inhibitory signal in mast cells to suppress production of LPS-induced inflammatory cytokines 
and chemokines. After cecal ligation and puncture (CLP), when a large number of cells 
undergo apoptosis in the peritoneal cavity, CD300a-deficient peritoneal mast cells produced 
more chemoattractant and recruited more neutrophils than did wild-type (WT) mast cells. 
As a result, CD300a-deficient mice showed increased neutrophil recruitment and improved 
bacterial clearance in the peritoneal cavity, and survived longer than WT mice. Antibody 
blockade of CD300a–PS interactions improved bacterial clearance and extended survival of 
WT mice subjected to CLP. These results indicated that CD300a is a nonphagocytic PS recep-
tor that regulates mast cell inflammatory responses to microbial infections.
© 2012 Nakahashi-Oda et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Gas6 (growth arrest–specific 6) and protein S, which are 
abundant in the plasma and bind PS and TAM family mem-
bers (Tyro3, Axl, and Mer), are also bridging molecules be-
tween apoptotic cells and phagocytes (Nakano et al., 1997; 
Scott et al., 2001). However, whether PS receptors deliver 
signals that lead to cellular responses other than phagocy-
tosis is unclear.
Activation of immune cells is regulated by positive and nega-
tive signals triggered by activating and inhibitory cell surface 
immunoreceptors, respectively. These immunoreceptors play 
important roles in regulation of immune responses (Ravetch 
and Lanier, 2000; Lanier, 2001). Inhibitory receptors are char-
acterized by the immunoreceptor tyrosine-based inhibition 
motif (ITIM) in their cytoplasmic domains. The prototype 
6-aa sequence for ITIM is (I/V/L/S)-x-Y-x-x-(L/V) (x denotes 
any amino acid), whose tyrosine is phosphorylated upon 
ligand binding, providing a docking site for the recruitment 
of SH2 (Src homology 2)–containing cytoplasmic phospha-
tases (Malbec et al., 1998; Smith et al., 1998) and shutting 
down activation signals by dephosphorylation of intracellular 
substrates at the earliest steps of the activation response. The 
ITIM-bearing cell surface immunoreceptors, including cer-
tain NK receptors, Fc receptors (FcRIIb), and others, play a 
central role in mediating negative signals in both lymphoid 
and myeloid cells (Daëron et al., 2008).
CD300 is a multigene family consisting of seven genes 
on human chromosome 17 (Clark et al., 2000, 2001). CD300 
molecules are member of Ig super family bearing one Ig-like 
domain in the extracellular portion. The mouse counterparts 
of CD300 molecules, which were reported to be as myeloid-
associated Ig-like receptor (MAIR; Yotsumoto et al., 2003; 
Okoshi et al., 2005; Nakahashi et al., 2007; Can et al., 2008; 
Nakano et al., 2008; Nakano-Yokomizo et al., 2011)/
CMRF-35–like molecule (CLM; Chung et al., 2003; Fujimoto 
et al., 2006; Xi et al., 2010)/leukocyte mono-Ig-like receptor 
(LMIR; Kumagai et al., 2003; Izawa et al., 2007; Enomoto 
et al., 2010)/DIgR (Luo et al., 2001; Shi et al., 2006), were 
encoded by nine genes on a small segment of mouse chro-
mosome 11, the syntenic region of human chromosome 17 
(Chung et al., 2003; Nakano et al., 2007). CD300 molecules 
are preferentially expressed on myeloid cells, including macro-
phages, neutrophils, DCs, and/or mast cells, and may regu-
late activation of these cells. One of the CD300 molecules, 
CD300a (also called MAIR-I [Yotsumoto et al., 2003], LMIR1 
[Kumagai et al., 2003], or CLM-8 [Chung et al., 2003] in 
mice, and IRp60 [Cantoni et al., 1999] or CMRF-35H [Clark 
et al., 2000] in human), has a long cytoplasmic region con-
taining the consensus ITIM sequence. Upon cross-linking with 
monoclonal antibodies, CD300a inhibits FcRI-mediated 
Figure 1. Generation of Cd300a/ mice. (A) The WT Cd300a allele, 
the targeting vector, the targeted allele, and the binding sites of the PCR 
primers are shown. (B) Genomic DNA from the tails of Cd300a/ (/), 
Cd300a+/ (+/), and WT (+/+) mice were analyzed for WT and mutant 
alleles by PCR. (C) mRNA expression of the genes neighboring Cd300a, 
including Cd300lb, Cd300ld, Cd300d, and Gpr142 in the spleen of WT and 
Cd300a/ mice was determined by PCR. -Actin, loading control. The blue 
line indicates the BAC clone containing the targeted allele. (D) Western 
blot analysis of BM cells from WT and Cd300a/ mice. Cells were lysed 
with 1% NP-40 lysis buffer and immunoblotted with an antibody to 
CD300a (or CD300d as a loading control). (E) Flow cytometric analysis of 
peritoneal resident macrophages and cultured BMMCs. Peritoneal exudate 
cells from WT and Cd300a/ mice were stained with FITC-conjugated anti-
CD11b, APC-conjugated F4/80 antibodies, and biotin-conjugated anti-CD300a, 
followed by PE-conjugated streptavidin. BMMCs from WT and Cd300a/ 
mice were stained with FITC-conjugated anti-FcRI, APC-conjugated  
anti–c-Kit, and biotin-conjugated anti-CD300a, followed by PE-conjugated 
streptavidin. These cells were then analyzed by flow cytometry. The open 
histograms show CD300a expression on the gates of CD11b+F4/80+ and  
c-Kit+ FcRI+ cells. The closed histograms show isotype control. Experi-
ments were performed three times with similar results. The results of 
one experiment are shown (B–E).
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laser-scanning confocal microscopy. In contrast to the paren-
tal NIH 3T3 cells, both CD300a and TIM-4 transfectants 
bound to apoptotic cells (Fig. 2 C). However, although TIM-4 
transfectant expressed a pHrodo signal, we could not detect any 
signals from CD300a transfectant (Fig. 2 C). Flow cytometry 
signals, resulting in the suppression of degranulation from 
human and mouse mast cells in vitro (Yotsumoto et al., 2003; 
Okoshi et al., 2005; Munitz et al., 2006; Karra et al., 2009). 
In addition, CD300a modulates inflammatory responses by 
myeloid cells (Alvarez et al., 2008; Ju et al., 2008). CD300a 
is also expressed on human—but not mouse—NK cells and 
involved in cytotoxic function (Cantoni et al., 1999; Lankry 
et al., 2010). We have recently identified CD300a as a new 
PS receptor (Nakahashi-Oda et al., 2012). However, the 
physiological role of CD300a remained undetermined.
To explore the physiological role of CD300a, we gener-
ated mice deficient in Cd300a. We describe that CD300a 
does not stimulate engulfment of apoptotic cells by phago-
cytes but, rather, inhibits inflammatory cytokine and chemo-
kine production from mast cells upon binding to PS in vitro 
and in vivo.
RESULTS
CD300a does not mediate phagocytosis
Several receptors for PS are expressed on phagocytes and are 
involved in clearing apoptotic cells in physiological and path-
ological settings (Scott et al., 2001; Hanayama et al., 2002; 
Kobayashi et al., 2007; Miyanishi et al., 2007; Park et al., 
2007, 2008). Because PS mediates an “eat-me” signal to 
phagocytes such as macrophages (Fadok et al., 1992; Savill 
et al., 2002), we generated CD300a-deficient (Cd300a/) 
mice (Fig. 1). Cd300a/ mice lacked the expression of 
Cd300a mRNA and CD300a protein but showed normal 
expression of neighboring genes to Cd300a in the Cd300 
family gene cluster on chromosome 11 (Fig. 1), indicating 
that Cd300a/ mice were correctly generated. We exam-
ined whether CD300a is involved in phagocytosis of apop-
totic cells by using macrophages from Cd300a/ mice and 
apoptotic thymocytes from caspase-activated DNase (CAD)/ 
mice. CAD/ cells do not undergo apoptotic DNA frag-
mentation, but their DNA is degraded in phagocytes after 
they are engulfed (Nagata, 2005). WT or Cd300a/ peritoneal 
resident macrophages were cocultured with dexamethasone-
induced apoptotic CAD/ thymocytes for 2 h, stained with 
TUNEL, and analyzed by laser-scanning confocal microscopy. 
The frequencies of WT and Cd300a/ peritoneal macro-
phages carrying a given number of apoptotic cells were 
comparable (Fig. 2 A). Peritoneal resident macrophages also 
express several receptors, including TIM-1, TIM-4, and V3 
(Kobayashi et al., 2007; Miyanishi et al., 2007; Fig. 3 A), that 
directly or indirectly bind PS and are involved in engulfment 
of apoptotic cells (Kuchroo et al., 2008). To examine whether 
these PS receptors had functional redundancy that masked the 
CD300a phagocytic function, we established NIH 3T3 trans-
fectants stably expressing either CD300a or TIM-4 (Fig. 2 B). 
We labeled apoptotic thymocytes with pHrodo succinimidyl 
ester, a pH-sensitive fluorescent dye, which can be detected 
when they are engulfed as a result of the increased post-
phagocytic light emission (Miksa et al., 2009). The NIH 3T3 
transfectants or parental NIH 3T3 cells were cocultured with 
pHrodo dye–labeled apoptotic thymocytes and analyzed by 
Figure 2. CD300a is not involved in phagocytosis of apoptotic 
cells by macrophages. (A) Apoptotic CAD/ thymocytes were cocul-
tured with peritoneal resident macrophages from Cd300a/ or WT mice 
and stained using TUNEL. More than 100 macrophages were randomly 
analyzed by using laser-scanning confocal microscopy, and the number of 
TUNEL-positive cells in each macrophage was determined. Error bars indi-
cate SD. (B–D) NIH 3T3 transfectants expressing CD300a and TIM-4 were 
stained with FITC-conjugated anti-CD300a and anti–TIM-4 (open histo-
gram), respectively, or FITC-conjugated control antibody (closed histo-
gram), and analyzed by flow cytometry (B). These transfectants were 
cocultured with pHrodo succinimidyl ester–labeled apoptotic thymocytes 
for 1 h, washed with PBS, fixed with paraformaldehyde, and then ana-
lyzed by laser-scanning confocal microscopy (C). The round cells under 
the light-field illumination indicate apoptotic thymocytes (C, top) and the 
pHrodo red signal under the dark-field illumination indicates engulfed 
apoptotic thymocytes (C, bottom). The arrows indicate the transfectants 
engulfing apoptotic cells (C). NIH 3T3 or NIH 3T3 transfectants were also 
analyzed by flow cytometry (D). Data are representative of more than 
three independent experiments (A–D).
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Figure 3. CD300a inhibits LPS-induced cytokine secretion from mast cells. (A) Expression of PS receptors. Peritoneal resident macrophages and 
BMMCs were stained with a biotin-conjugated monoclonal antibody to TIM-1 followed by PE-conjugated streptavidin, a PE-conjugated monoclonal anti-
body to TIM-4, and an Alexa Fluor 647–conjugated monoclonal antibody to mouse CD300a (open histograms), and analyzed by flow cytometry. The closed 
histograms show isotype control. These cells were also subjected to RT-PCR to analyze expression of mRNA indicated. (B–D) WT or Cd300a/ BMMCs 
mixed with apoptotic cells at a ratio of 1:0.1 were stimulated with 1 µg/ml LPS for 4 h. The culture supernatant was subjected to proteome analyses (B) or 
ELISA (C; n = 6) in the absence (B and C) or presence (C) of D89E MFG-E8. After culture, intracellular cytokine staining was also performed in BMMCs  
(D; n = 6). (E–G) RBL-2H3 transfectants expressing Flag-tagged WT or mutated CD300a, in which the tyrosines Y233, Y258, Y270, and/or Y299 were replaced 
with phenylalanine or the cytoplasmic region was deleted (Del; E), were cocultured with apoptotic cells at a ratio of 1:0.1 in the presence of 100 ng/ml 
LPS for 4 h (F) or the indicated times (G). Cells were immunoprecipitated with anti-Flag and immunoblotted with anti–SHP-1 (F), anti-phosphotyrosine 
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(G), or anti-Flag (F and G). (H and I) BMMCs were transfected with control siRNA (Ctrl) or SHP-1 siRNA and analyzed by immunoblotting with antibodies  
indicated (H). The mixture of these BMMCs and apoptotic cells were stimulated with 1 µg/ml LPS for 4 h and analyzed for TNF production by ELISA (I; n = 3).  
(J and K) Cd300a/ or WT peritoneal resident macrophages were cocultured with apoptotic cells at a ratio of 1:0.1 in the presence of LPS for 4 h, immuno-
precipitated with anti-CD300a, and immunoblotted with anti–SHP-1 or anti-CD300a (J). TNF and IL-10 in the culture supernatants were analyzed by 
ELISA (n = 3; K). Data are representative of three independent experiments. *, P < 0.05; **, P < 0.01, Student’s t test. Error bars show SD.
 
analyses also demonstrated that a pHrodo signal was de-
tected only in TIM-4, but not CD300a, transfectant (Fig. 
2 D). Together, these results indicated that CD300a does not 
mediate phagocytosis of apoptotic cells by macrophages.
PS delivers an inhibitory signal in mast cells via CD300a
CD300a is also expressed on mast cells. To address whether 
apoptotic cells affect mast cell activation via CD300a, we 
generated BM-derived mast cells (BMMCs) from Cd300a/ 
or WT mice. Unlike macrophages, mast cells do not express 
the PS receptors TIM-1, TIM-4, and stabilin-2, although 
they do express CD300a and V integrin (Fig. 3 A). We 
examined whether PS binding to CD300a has any effect 
on LPS-induced cytokine or chemokine production from 
BMMCs by proteome analyses. WT or Cd300a/ BMMCs 
were cocultured with apoptotic cells at a ratio of 1:0.1 in the 
presence of LPS for 4 h. Cd300a/ BMMCs produced 
greater amounts of several chemokines and cytokines, including 
MCP-1 and IL-13, compared with WT BMMCs (Fig. 3 B). 
We therefore performed quantitative analysis of MCP-1 and 
IL-13 in addition to a proinflammatory cytokine TNF by 
ELISA. Although we did not detect any cytokines or che-
mokines in the culture supernatants in the absence of stimuli, 
stimulation with 1 µg/ml LPS induced both WT and Cd300a/ 
BMMCs to produce TNF, IL-13, and MCP-1; however, 
Cd300a/ BMMCs produced them at significantly higher 
concentrations (Fig. 3 C). Flow cytometry analyses also detected 
significantly more of these cytokines and chemokines in the 
cytoplasm of Cd300a/ BMMCs than in the cytoplasm of 
WT BMMCs 4 h after stimulation with LPS (Fig. 3 D). How-
ever, in the presence of a variant of MFG-E8 containing a 
point mutation (D89E) in the RGD motif (D89E MFG-E8), 
which is able to bind PS but is not able to bind V3 integrin 
(Hanayama et al., 2002), the levels of these cytokines and chemo-
kines became comparable in WT and Cd300a/ BMMCs 
(Fig. 3 C), suggesting that CD300a–PS interaction inhibits 
these cytokines’ and chemokines’ production from BMMCs.
CD300a contains the five tyrosines at residues 233, 258, 270, 
299, and 313 in the cytoplasmic domain, and Y258 and Y270 
consist of the consensus ITIM sequence ((I/V/L/S)xYxx(L/V)). 
We previously reported that Y258 and Y270 are responsible for 
phosphorylation of CD300a and recruitment of SHP-1 in a rat 
basophilic leukemia cell line (RBL-2H3) upon stimulation 
with pervanadate (Okoshi et al., 2005). We found that Y258 
and/or Y270 were phosphorylated and involved in SHP-1 
recruitment in RBL-2H3 transfectants expressing WT or 
mutated CD300a when these cells were cocultured with 
apoptotic cells in the presence of LPS (Fig. 3, E–G). We have 
recently reported that CD300a also recruited SHP-1 in 
BMMCs when BMMCs were cocultured with apoptotic 
cells in the presence of LPS (Nakahashi-Oda et al., 2012). To 
examine whether SHP-1 is involved in CD300a-mediated 
signaling, we knocked down Ptpn6 with a small interfering 
RNA (siRNA) to create SHP-1–deficient (Ptpn6-KD) WT 
and Cd300a/ BMMCs (Fig. 3 H). Whereas the control 
Cd300a/ BMMCs produced significantly more TNF than 
did WT BMMCs after stimulation with LPS for 4 h, there 
was no significant difference in TNF production between 
Ptpn6-KD WT and Ptpn6-KD Cd300a/ BMMCs (Fig. 3 I). 
Collectively, these results indicate that upon binding to PS, 
CD300a recruits SHP-1 and mediates an inhibitory signal 
in BMMCs, resulting in the suppression of cytokines and 
chemokines secretion.
We next examined whether CD300a also recruits SHP-1 
and delivers an inhibitory signal in macrophages upon binding 
to PS. WT or Cd300a/ peritoneal resident macrophages 
were cocultured with apoptotic thymocytes at 1:0.1 ratios 
in the presence of LPS, demonstrating that CD300a also 
recruited SHP-1 in peritoneal resident macrophages (Fig. 3 J). 
Moreover, the production of TNF and IL-10 by Cd300a/ 
peritoneal macrophages was significantly greater than that by 
WT peritoneal macrophages (Fig. 3 K), indicating that PS 
binding of CD300a inhibits cytokine production by macro-
phages as well as mast cells.
CD300a-deficient mice show longer survival  
after cecal ligation and puncture (CLP)
TNF, IL-13, and MCP-1 produced by mast cells are che-
moattractants for neutrophils and play an important role in 
bacterial clearance in a CLP peritonitis model in mice 
(Echtenacher et al., 1996; Malaviya et al., 1996; Baumhofer 
et al., 1998; Matsukawa et al., 1999; Marshall, 2004). Therefore, 
we hypothesized that CD300a affects immune regulation by 
mast cells at the site of peritonitis, where large numbers of 
cells undergo apoptosis in the peritoneal cavity (Hotchkiss 
and Nicholson, 2006). In fact, we observed that >10% of 
cells in the peritoneal cavity 4 h after CLP were apoptotic 
cells, as determined by staining with Annexin V (Fig. 4 A). 
To test the hypothesis, we subjected WT and Cd300a/ 
mice to CLP and observed that Cd300a/ mice survived 
significantly longer than did WT mice after CLP (Fig. 4 B).
To elucidate the mechanism responsible for the longer 
survival advantage of the Cd300a / mice in this model, we 
measured bacterial content in the peritoneal cavity 4 h after 
CLP. Cd300a/ mice had significantly fewer bacterial colony-
forming units (CFUs) than did WT mice (Fig. 4 C). Because 
we did not observe any differences in the number and type 
of commensal bacteria between the two mouse genotypes 
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results indicated that 
neutrophils play an 
important role in 
the survival of mice 
after CLP.
CD300a on mast cells is critical for survival of mice after CLP
In the early phase of the CLP peritonitis model, mast cells 
play an important role in recruitment of neutrophils into the 
peritoneal cavity by secretion of chemoattractants for neutro-
phils, such as TNF, and prolong the survival (Echtenacher 
et al., 1996; Malaviya et al., 1996). We have demonstrated 
that Cd300a/ BMMCs produced more chemoattractants 
for neutrophils—including TNF, IL-13, and MCP-1—in 
response to LPS than WT BMMCs in vitro (Fig. 3, C and D). 
To examine whether CD300a on mast cells is involved in neu-
trophil recruitment and longer survival, WT and Cd300a/ 
BMMCs were or were not transferred into the peritoneal 
cavities of KitW-sh/W-sh mice—which are deficient in mast cells 
(Grimbaldeston et al., 2005)—before CLP. After CLP, KitW-sh/W-sh 
mice that received WT BMMCs survived significantly longer 
than those that did not receive any BMMCs (Fig. 5 A), which 
is consistent with previous studies (Echtenacher et al., 1996; 
Malaviya et al., 1996). However, KitW-sh/W-sh mice that received 
Cd300a/ BMMCs showed significantly longer survival 
after CLP and significantly greater bacterial clearance than 
(unpublished data), these results suggested that Cd300a/ mice 
had more efficient bacterial clearance. We therefore examined 
the number of phagocytes in the peritoneal cavity after CLP. 
Cd300a/ mice had significantly greater numbers of neutro-
phils than did WT mice 4 h after CLP (Fig. 4 D). However, mac-
rophage numbers were comparable between the two genotypes 
(Fig. 4 D). Because Cd300a/ peritoneal resident macro-
phages did not differ in the phagocytic function of Escherichia 
coli from those from WT mice (Fig. 4 E), these results sug-
gested that the increased numbers of neutrophils in Cd300a/ 
mice contributed to the enhanced bacterial clearance, which 
in turn led to the decreased mortality rates after CLP.
To verify the important role of neutrophils, but not 
macrophages, in the lower mortality rates in Cd300a/ 
mice, we generated WT and Cd300a/ mice lacking neu-
trophils as a result of injection with anti–Gr-1 monoclonal 
antibody or fewer macrophages as a result of injection with 
clodronate liposomes. Flow cytometric analyses demon-
strated that the neutrophils or macrophages were efficiently 
depleted in these mice (Fig. 4 F). Depletion of neutrophils 
rendered the survival rates of both mouse genotypes com-
parable (Fig. 4 G), indicating that neutrophils played an 
important role in improving the mortality rate of Cd300a/ 
mice after CLP. In contrast, there was still a significant dif-
ference in survival duration between WT and Cd300a/ 
mice in which macrophages were depleted (Fig. 4 H). These 
Figure 4. CD300a-deficient mice showed 
longer survival after CLP. (A–D) WT and 
Cd300a/ mice were subjected to CLP.  
Before and 4 h after CLP, cells in the perito-
neal lavage fluid of WT mice were stained 
with APC-conjugated Annexin V and CD300a-Fc, 
followed by FITC-conjugated anti–human  
IgG and PI, and analyzed by flow cytometry  
(A). Data are representative from three mice. 
(B) The survival rate after CLP is shown  
(n = 20 WT mice and n = 21 Cd300a/ mice. 
Data were pooled from two independent 
experiments.). Bacterial CFUs (C) and the 
numbers of neutrophils and macrophages  
(D) in the peritoneal lavage fluid of WT and 
Cd300a/ mice (n = 5 in each group) were 
determined 4 h after CLP. (E) Peritoneal resi-
dent macrophages from Cd300a/ and WT 
mice (n = 5 in each group) were cocultured 
with fluorescein-labeled Escherichia coli  
for 1 h in a 24-well plate and analyzed by 
flow cytometry. The frequencies of macro-
phages ingesting Escherichia coli are shown. 
(F–H) Cd300a/ and WT mice were injected 
intraperitoneally with clodronate liposomes 
to deplete macrophages or an antibody to  
Gr-1 to deplete neutrophils. The respective 
controls were injected with PBS liposomes  
or control Ig. 24 h later, peritoneal lavage 
fluid cells were stained with the antibodies 
indicated and analyzed by flow cytometry. 
Data are representative of three mice in  
each group of WT mice, and similar results 
were obtained in each group of Cd300a/ 
mice (F). The survival rate after CLP was 
shown (n = 9 in each group. Data were  
pooled from two independent experiments;  
G and H). *, P < 0.05, Student’s t test. Error 
bars show SD.
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those that received WT BMMCs (Fig. 5, A and B), suggesting 
that Cd300a/ BMMCs produced a greater amount of 
chemoattractants for neutrophils than did WT BMMCs in 
the peritoneal cavity after CLP. To directly confirm this 
idea, KitW-sh/W-sh mice received a 1:1 mixture of CFSE-labeled 
WT and Cd300a/ BMMCs via the peritoneal cavity and 
were subjected to CLP. Although both WT and Cd300a/ 
BMMCs transferred into the peritoneal cavity showed a low 
level of TNF expression, Cd300a/ BMMCs, defined as 
CD300aCFSE+ cells, showed significantly higher frequency 
in the BMMCs producing a high level of TNF than did WT 
(CD300a+CFSE+) BMMCs (Fig. 5 C). Together, these results 
indicate that CD300a inhibits production of chemoattractants 
for neutrophils from BMMCs in the peritoneal cavity after 
CLP. Although BMMC transfer into KitW-sh/W-sh mice does 
not completely reconstitute the immune system in KitW-sh/W-sh 
mice (Dudeck et al., 2011), our results suggested that CD300a 
on mast cells was primarily responsible for the phenotype of 
prolonged survival of Cd300a/ mice after CLP.
Blockade of CD300a–PS interaction prolonged  
survival of mice after CLP
Because Cd300a/ mice survived longer after CLP, we 
examined whether an antibody against mouse CD300a (TX41) 
could have a prophylactic effect on CLP-induced sepsis. TX41 
does not deplete myeloid cells, including mast cells. Intra-
peritoneal injection of mice with TX41 1 h before and 18 h 
after CLP significantly increased neutrophil numbers in 
the peritoneal cavity, improved bacterial clearance 4 h after 
CLP, and prolonged survival compared with treatment with 
a control antibody (Fig. 6, A–C). Similarly, intraperitoneal 
injection with D89E MFG-E8 also prolonged survival of 
WT mice compared with treatment with PBS. In contrast, 
D89E MFG-E8 did not change the survival of 
Cd300a/ mice, indicating that D89E MFG-E8 
blocked the interaction between PS and CD300a, 
but not other PS receptors (Fig. 6 D). Moreover, 
D89E MFG-E8 improved bacterial clearance of 
WT mice (Fig. 6 E). These results provided the 
formal evidence that PS on apoptotic cells affected 
Figure 5. CD300a on mast cells is critical for survival after CLP.  
(A and B) KitW-sh/W-sh mice were injected i.p., or not injected, with BMMCs 
from WT or Cd300a/ mice, and then 28 d later, CLP was performed (n = 20 
in each group, data were pooled from two independent experiments) and 
the survival rate was shown (A). Bacterial CFUs in the peritoneal lavage 
fluid of mice transferred with Cd300a/ (n = 4) and WT (n = 4) BMMCs 
were assayed 4 h after CLP (B). (C) KitW-sh/W-sh mice were injected i.p. with a 
1:1 mixture of CFSE-labeled Cd300a/ and WT BMMCs 24 h before CLP. 
CFSE-labeled cells in the peritoneal lavage fluid of mice 4 h after CLP were 
analyzed by flow cytometry. Data are representative of three independent 
experiments. *, P < 0.05, Student’s t test. Error bars show SD.
Figure 6. The blockade of the CD300a–PS interaction 
prolongs survival of mice after CLP. (A–C) WT mice were 
injected i.p. with 500 µg of control antibody (n = 11) or anti-
CD300a monoclonal antibody (TX41; n = 13), 1 h before and 
18 h after CLP, and the survival rate is shown (A). Bacterial 
CFUs (B) and the numbers of neutrophils (C) in the perito-
neal lavage fluid of mice (n = 5 in each group) were deter-
mined 4 h after CLP, as described. (D and E) WT or Cd300a/ 
mice were injected i.p. with 50 µg D89E MFG-E8 (n = 10 and 
8, respectively) or PBS (n = 9), 1 h before and 18 h after CLP, 
and the survival rate is shown (D). Bacterial CFUs in the 
peritoneal lavage fluid of mice (n = 4 in each group) were 
determined 4 h after CLP, as described (E). *, P < 0.05,  
Student’s t test. Error bars show SD. Data in A and D were 
each pooled from two independent experiments.
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these cells were cocultured with apoptotic cells in the 
presence of LPS. However, because SHP-1 recruitment by 
CD300a that is essential for CD300a-mediated inhibitory 
signal requires both PS binding and LPS stimulation in mac-
rophages as well as mast cells, it is unlikely that CD300a on 
macrophages is involved in the noninflammatory nature of 
phagocytosis of apoptotic cells mediated by PS receptors other 
than CD300a in the physiological conditions. Further studies 
should be required to clarify the regulatory role of CD300a 
in activation of myeloid cells, including dendritic cells and 
neutrophils as well as mast cells and macrophages. Nonethe-
less, CD300a is the first PS receptor identified on mast cells 
and suppresses inflammatory responses by mast cells.
Sepsis, the systemic inflammatory syndrome induced 
by severe infections, remains a leading cause of death world-
wide (Angus and Wax, 2001; Cohen, 2002). Despite extensive 
basic and clinical research, the pathophysiology of sepsis is 
still poorly understood, and trials of several therapies have 
failed to improve the prognosis of septic patients in large 
multicenter clinical trials (Riedemann et al., 2003; Russell, 
2006). The best established mouse model of sepsis, CLP, has 
shown that mast cells play essential roles in host defense 
against CLP (Malaviya et al., 1996). Here, we provide compel-
ling experimental evidence supporting the efficacy of anti-
CD300a monoclonal antibody and D89E MFG-E8 adjunctive 
therapy for polymicrobial peritonitis-induced sepsis. Both 
anti-CD300a and D89E MFG-E8 blocked the binding of PS 
to CD300a, resulting in the increased production of che-
moattractants for neutrophils from mast cells induced by LPS 
in the peritoneal cavity. Long-term treatment with D89E 
MFG-E8 leads to the development of autoimmune diseases 
as a result of the defect of apoptotic cell clearance (Hanayama 
et al., 2004). However, we injected D89E MFG-E8 only 
twice before CLP and 18 h after CLP, which was enough for 
the prophylaxis of peritonitis-induced sepsis. Mast cell activa-
tion is important in the very early phase after infection, only 
when the blocking CD300a-mediated signaling by D89E 
MFG-E8 or anti-CD300a antibody should be required.
The classical function of mast cells is involved in allergic 
responses, in which FcRI-mediated signals lead to degranulation 
from mast cells (Gilfillan and Tkaczyk, 2006). In vitro analyses 
demonstrated that cross-linking CD300a with monoclonal 
antibody suppressed FcRI-mediated signals, resulting in the 
decreased degranulation in human and mice (Yotsumoto 
et al., 2003; Okoshi et al., 2005; Munitz et al., 2006; Karra et al., 
2009). Because many cells undergo apoptosis at the site of allergic 
inflammation, CD300a may play an important role in allergic 
responses by mast cells and may be a potential prophylaxis and/
or therapeutic target for treatment of allergic diseases.
MATERIALS AND METHODS
Mice. To construct the CD300a targeting vector, we replaced exon 1 to exon 6 
of the Cd300a gene with a neomycin-resistance gene cassette (PGK-GB2-neo) 
using the bacterial artificial chromosome (BAC) system (Yang and Seed, 2003). 
BALB/c embryonic stem cells were electroporated with linearized Cd300a 
targeting vector, and cells were selected for G418 antibiotic resistance. 
the bacterial clearance. Thus, blocking the interaction between 
PS and its receptor CD300a is potentially a useful therapy 
for prophylaxis against peritonitis-induced sepsis.
DISCUSSION
A large number of cells undergo apoptosis every day in physio-
logical and pathological settings. PS receptors play a central 
role in engulfment of apoptotic cells and are crucial to avoiding 
the development of autoimmune diseases (Hanayama et al., 
2004). Pathological conditions such as microbial infections 
significantly augment cell death by apoptosis (Hotchkiss and 
Nicholson, 2006) and trigger the first line of inflammatory re-
sponses by mast cells through receptors for pathogen-associated 
molecular patterns such as Toll-like receptors (Marshall, 2004; 
Bischoff, 2007; Abraham and St John, 2010). Mast cells there-
fore play an important role in the early phase of immunity 
against microbial pathogens. Our results indicate that PS not 
only delivers “eat-me” signals to phagocytes via PS receptors 
but also suppresses inflammatory responses by mast cells and 
macrophages via CD300a.
Although CD300a is expressed on professional phagocytes, 
such as macrophages and dendritic cells (Yotsumoto et al., 
2003), we did not observe CD300a-mediated phagocytosis 
of apoptotic cells by macrophages. Because CD300a asso-
ciates with SHP-1 upon ligand binding and inhibits activa-
tion signals, CD300a may not have a functional property of 
phagocytosis. However, it cannot be excluded that the CD300a-
mediated signal suppresses, rather than augments, phagocy-
tosis by other PS receptors such as TIM-4 (Kobayashi et al., 
2007), if PS binding could be shared by CD300a and TIM-4 
on a macrophage. This may depend on the binding affinity 
of these receptors to PS. At present, the affinity of CD300a 
binding to PS has remained undetermined. Very recently, 
Choi et al. (2011) have reported that CD300f also recog-
nizes PS and exogenous expression of CD300f enhanced 
phagocytosis of apoptotic cells by fibroblast cell line L929 
cells. Like CD300a, CD300f contains ITIM in the cytoplas-
mic portion. Upon cross-linking with antibody, the ITIM of 
CD300f is phosphorylated, recruits SHP-1 and SHP-2, and 
mediates an inhibitory signal in myeloid cells (Izawa et al., 
2009). It is unclear, however, how CD300f-mediated signal-
ing involves phagocytosis of apoptotic cells.
One of the key biological features of apoptotic cell engulf-
ment by phagocytes is the noninflammatory nature (Fadok 
et al., 1998; Ravichandran and Lorenz, 2007). The molecular 
mechanism under this feature has still remained unclear. The 
suppressive effect of CD300a on the proinflammatory cytokine 
and chemokine production by mast cells does not necessarily 
account for this feature because mast cells are not phagocytes 
and their activation is induced by pathological conditions such 
as microbial infections. However, it may contribute to avoiding 
excessive inflammations by suppressing mast cell–mediated trig-
gering of inflammation. Our data showed that CD300a defi-
ciency also affected the production of both the proinflammatory 
and antiinflammatory cytokines TNF and IL-10, respectively, 
without selectivity by peritoneal resident macrophages, when 
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ventral abdomen, ligated at its distal portion, and punctured twice with a 
27-gauge needle in the ligated segment. We then returned the cecum to 
the abdomen, injected 1 ml of sterile saline subcutaneously for rehydration, and 
closed the incision by suture.
Measurement of cytokines and chemokines. The concentrations of 
cytokines and chemokines were measured in triplicate using ELISA kits from 
BD (TNF) and R&D Systems (MCP-1 and IL-13). Intracellular cytokines and 
chemokines were analyzed by flow cytometry after fixation and permeabilization 
using a Fix & Perm cell fixation and permeabilization kit (Invitrogen). The 
supernatant of the co-culture of BMMC with apoptotic cells was subjected to 
cytokine and chemokine proteome analyses with a Proteome Profiler Array 
(R&D Systems) in accordance with the manufacturer’s instructions.
Measurement of CFUs of aerobic bacteria. Aerobic bacterial CFUs 
were quantified by plating serial dilutions of peritoneal lavage fluid and cul-
turing them at 37°C for 48 h on brain-heart-infusion agar plates. CFUs were 
then enumerated by calculating the number of colonies in 1 ml peritoneal 
lavage fluid, as previously described (Plitas et al., 2008).
In vivo depletion of macrophages and neutrophils. For macrophage 
depletion, clodronate liposomes and control PBS liposomes (Encapsula 
NanoSciences) were prepared as previously described (Van Rooijen, 1989). 
Mice were injected i.p. with 0.5 ml liposomes 24 h before CLP. For neutrophil 
depletion, mice were injected i.p. with 5 µg anti–Gr-1, 24 h before CLP. 
WT or Cd300a/ neutrophils (1 × 106/mice) purified from the BM were 
injected into some neutrophil-depleted mice just after CLP.
RNA interference. To target SHP-1 in BMMCs, 0.5 mM SHP-1 siRNA 
(siGENOME SMARTpool; Thermo Fisher Scientific) was mixed with 1 µl 
X-tremeGENE siRNA transfection reagent (Roche) and transfected into 5 × 
105 BMMCs, as previously described (An et al., 2006). After 48 h, the super-
natant was removed, and fresh medium and 0.3 mM SHP-1 siRNA were 
added. The cells were cultured for another 16 h before further experiments.
Statistical analyses. The Kaplan-Meier log-rank test was used for survival 
analyses. All other statistical analyses were performed using an unpaired 
Student’s t test. P < 0.05 was considered statistically significant.
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